1AI — Algorae Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- AU$8.44m
- AU$6.03m
- AU$0.13m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.53 | ||
| Price to Tang. Book | 3.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 62.69 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.81% | ||
| Return on Equity | -43.16% | ||
| Operating Margin | -938.24% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.55 | 0.27 | 0 | 0.04 | 0.13 | n/a | n/a | -30.46% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI) enabled drug discovery and development company. The Company is actively engaged in expanding its therapeutic pipeline using a proprietary artificial intelligence (AI) drug discovery and development platform, known as Algorae Operating System (AlgoraeOS). The AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the AlgoraeOS is focused on uncovering synergistic fixed dose drug combinations that lead to the development of effective treatments for any medical condition. It is also focused on advancing its drug candidates, which include AI-116 for the treatment of neurodegenerative disorders and/or dementia, and AI-168 for cardiovascular disease and NTCELL for Parkinson’s disease.
Directors
- Bernie Tuch CHM
- Daya Uka CFO
- John Cowan FID
- Belinda Di Bartolo COO
- Mark Licciardo SEC
- Andrew Kelly NED
- Carolyn Sue NED
- Robert Willcocks IND (65)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 17th, 2003
- Public Since
- September 1st, 2004
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,687,394,731
- Address
- Level 23,, Rialto South Tower,,, MELBOURNE, 3000
- Web
- https://algoraepharma.com/
- Phone
- +61 300288664
- Auditors
- PKF Brisbane Audit
Upcoming Events for 1AI
Algorae Pharmaceuticals Ltd Annual Shareholders Meeting
Similar to 1AI
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
Anteotech
Australian Stock Exchange - SEATS
FAQ
What is the Algorae Pharmaceuticals share price?
As of Today at 19:10 UTC, shares in Algorae Pharmaceuticals are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Algorae Pharmaceuticals share price performed this year?
Shares in Algorae Pharmaceuticals last closed at AU$0.01 and the price had moved by -50% over the past 365 days. In terms of relative price strength the Algorae Pharmaceuticals share price has underperformed the ASX All Ordinaries Index by -52.07% over the past year.
What are the analyst and broker recommendations for Algorae Pharmaceuticals?
There is no consensus recommendation for this security.
Find out moreWhat is the Algorae Pharmaceuticals dividend yield?
Algorae Pharmaceuticals does not currently pay a dividend.
Does Algorae Pharmaceuticals pay a dividend?
Algorae Pharmaceuticals does not currently pay a dividend.
When does Algorae Pharmaceuticals next pay dividends?
Algorae Pharmaceuticals does not currently pay a dividend.
How do I buy Algorae Pharmaceuticals shares?
To buy shares in Algorae Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Algorae Pharmaceuticals?
As of the previous close price of AU$0.01, shares in Algorae Pharmaceuticals had a market capitalisation of AU$8.44m.
Where are Algorae Pharmaceuticals shares listed?
Here are the trading details for Algorae Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: 1AI
What kind of share is Algorae Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Algorae Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Algorae Pharmaceuticals share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Algorae Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Algorae Pharmaceuticals. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -13.58%.
As of the last closing price of AU$0.01, shares in Algorae Pharmaceuticals were trading -31.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Algorae Pharmaceuticals PE Ratio?
The Algorae Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Algorae Pharmaceuticals?
Algorae Pharmaceuticals' management team is headed by:
- Bernie Tuch - CHM
- Daya Uka - CFO
- John Cowan - FID
- Belinda Di Bartolo - COO
- Mark Licciardo - SEC
- Andrew Kelly - NED
- Carolyn Sue - NED
- Robert Willcocks - IND